June 28, 2018 05:49 PM EDT

Finally, Celgene wins. Anemia drug luspatercept — partnered with Acceleron — scores in PhIII trial

Brittany Meiling

After Celgene’s many trips and blunders this year, the pharma giant might finally please investors Thursday with cheery news from one of its late-stage blockbuster hopefuls. The company reported its anemia drug luspatercept has met primary and secondary endpoints in a Phase III trial.

Celgene $CELG, which is partnered with Acceleron on the drug, said luspatercept “significantly” reduced the need for blood transfusions in patients with the blood disease myelodysplastic syndrome (MDS).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Finally, Celgene wins. Anemia drug luspatercept — partnered with Acceleron — scores in PhIII trial

Brittany Meiling

Unlock this article instantly by becoming a free subscriber.

Cash, chips and talent: Inside Nvidia's plan to dominate biotech's AI revolution

A majority of pharma and biotech companies prohibit ChatGPT use, survey finds

Senate bill targeting WuXi won't affect federal spending, CBO says

GSK unveils long-term Shingrix data as shingles competition heats up

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Fi­nal­ly, Cel­gene wins. Ane­mia drug lus­pa­ter­cept — part­nered with Ac­celeron — scores in PhI­II tri­al

Brittany Meiling

Unlock this article instantly by becoming a free subscriber.

more like this

Cash, chips and tal­ent: In­side Nvidi­a's plan to dom­i­nate biotech's AI rev­o­lu­tion

A ma­jor­i­ty of phar­ma and biotech com­pa­nies pro­hib­it Chat­G­PT use, sur­vey finds

Sen­ate bill tar­get­ing WuXi won't af­fect fed­er­al spend­ing, CBO says

GSK un­veils long-term Shin­grix da­ta as shin­gles com­pe­ti­tion heats up

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

Finally, Celgene wins. Anemia drug luspatercept — partnered with Acceleron — scores in PhIII trial

Cash, chips and talent: Inside Nvidia's plan to dominate biotech's AI revolution

A majority of pharma and biotech companies prohibit ChatGPT use, survey finds

Senate bill targeting WuXi won't affect federal spending, CBO says

GSK unveils long-term Shingrix data as shingles competition heats up

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Rare neuro disorder offers new area for competition, analysts say: #AAN24